What Athyrium Capital Management LP does

Athyrium Capital Management LP is a specialized healthcare-focused investment management firm founded in 2008 and headquartered at 505 Fifth Avenue, New York City. The firm provides structured financing solutions—including direct lending, acquisition financing, royalty monetization, and special situations investments—to commercial-stage healthcare companies globally. Its investment universe spans biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices, with individual investment sizes up to $200 million and the ability to upsize opportunistically.

Athyrium manages four flagship vehicles—Athyrium Opportunities Funds I through IV—with over $4.6 billion of committed capital and has invested more than $5 billion across 85+ portfolio companies since inception. The firm operates a B2B institutional model, serving two customer constituencies: portfolio companies (as financing provider) and limited partners (institutional investors including public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds). Revenue is generated through management fees on advised funds under multi-year recurring structures.

The firm maintains a longstanding 2009 strategic partnership with Neuberger Berman, which provides institutional LP distribution and co-manages healthcare credit vehicles. Athyrium's investment team of 20+ professionals is led by Managing Partner Jeffrey A. Ferrell (founder, 25+ years of life sciences investing experience, Harvard) and Partner Laurent D. Hermouet (founding member, CFA), supported by senior advisors with operating backgrounds at Cubist, Mylan, Cigna, and other major healthcare companies.

Name

Athyrium Capital Management LP

Legal name

Athyrium Capital Management, LP

Website

https://athyrium.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Athyrium Capital Management is a New York-based, healthcare-focused asset manager founded in 2008 that manages $4.6B+ across four funds. It provides structured financing—direct lending, royalties, acquisition financing, and convertible notes—to 85+ commercial-stage biotech, pharma, and healthcare companies globally.

Ownership category

akta.pro rank

Product category

Healthcare Asset Management

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Advisory Portfolio Management (Non-Discretionary) (FSAAABAD)

akta.pro secondary industries

Institutional Capital Introduction (LP/Family Office/Endowment Matching) (FSAEALAI), Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Healthcare asset management
• Structured healthcare financing
• Direct lending services
• Royalty financing solutions
• Special situations investing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Asset Management Fees: Athyrium earns management fees by advising funds with over $4.6 billion of committed capital. The firm manages multiple investment vehicles including Athyrium Opportunities Funds I-IV and has partnered with Neuberger Berman on healthcare credit strategies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Athyrium Capital Management is a specialized healthcare-focused investment management firm that manages multiple private investment funds (Athyrium Opportunities Funds I–IV) with over $4.6 billion of committed capital. The firm provides structured financing solutions including direct lending, acquisition financing, growth capital, royalty monetization, and special situations investments to commercial-stage healthcare and life sciences companies globally, with individual investments of up to $200 million per transaction.

Product overview

Athyrium Capital Management LP is a specialized healthcare investment management platform that offers structured financing solutions and investment vehicles across the healthcare and life sciences sectors. The firm operates multiple fund vehicles (Athyrium Opportunities Fund I, II, III, and IV) providing flexible capital to public and private healthcare companies. The platform focuses on biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices/products sectors, offering growth financing, debt instruments, royalty monetization, and structured investments to portfolio companies with committed capital exceeding $4.6 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• Athyrium Opportunities Fund I
• Athyrium Opportunities Fund II
• Athyrium Opportunities Fund III
• Athyrium Opportunities Fund IV
• Healthcare Investment Management Platform

Quantifiable outcome

• $5 billion+ in capital invested across 85+ portfolio companies since founding in 2008

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Royalty Pharma: Royalty Pharma is the largest healthcare royalty buyer and a publicly listed leader in biopharma royalty financing. While larger and more focused on larger/mega-deal royalties than Athyrium, it is a directly comparable buyer of healthcare cash-flow streams (e.g., the BioCryst $325M funding alongside Athyrium).
• OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms across private equity, venture, and royalty/credit strategies. It overlaps with Athyrium in healthcare private credit and structured capital while operating a much broader, multi-strategy platform.
• Blackstone Life Sciences: Blackstone Life Sciences is the life sciences arm of Blackstone investing across private equity, credit, and royalties in biopharma. It is a scaled incumbent competing for healthcare structured finance opportunities alongside Athyrium.
• KKR Health Care Strategic Growth: KKR's healthcare platform invests across healthcare services, pharma, and life sciences credit. Its scale, multi-product offerings, and institutional LP access make it a comparable broad incumbent in healthcare credit and growth investing.

Regional players

• Avista Capital Partners: Avista Capital Partners is a healthcare-focused private equity firm (and a former employer of Athyrium Partner Mark Kavulich). It pursues growth equity and buyouts in healthcare, overlapping thematically with Athyrium's growth capital and structured equity transactions in the healthcare sector.

Direct peers

• NovaQuest Capital Management: NovaQuest is a specialist asset manager focused on structured financing and royalty monetization for life sciences companies, with a similar product mix (royalty, milestone, debt) and healthcare-only mandate as Athyrium. It is one of the closest direct competitors in mid-market healthcare structured capital.
• HealthCare Royalty Partners: HealthCare Royalty Partners is a healthcare-focused structured finance and royalty investment firm that provides capital to healthcare and life sciences companies, directly overlapping with Athyrium's healthcare credit, royalty, and structured equity strategy. The two firms have even co-invested (e.g., Portola Pharmaceuticals $125M loan in 2019).
• BioPharma Credit: BioPharma Credit is a publicly traded specialty finance investor focused on debt and royalty financing for the biopharma sector. Its exclusive healthcare credit mandate mirrors Athyrium's strategy and target issuer base.
• Pharmstandard / Pharmakon Advisors: Pharmakon Advisors is a healthcare-focused structured capital provider offering senior secured loans and royalty-style financing to commercial-stage life sciences companies, with a product mix very similar to Athyrium's direct lending and royalty offerings.

Emerging players

• BridgeBio Pharma Capital: BridgeBio operates as a genetic disease-focused biotech but has built a sizable balance sheet and structured financing relationships. As an emerging, healthcare-focused capital allocator with growing financing activities, it is a thematic adjacent peer in the healthcare credit ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/athyrium-capital-management-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Athyrium Capital Management LP